This is a preview of subscription content, log in via an institution to check access.
Notes
United Kingdom Prospective Diabetes Study
Costs included those associated with the treatment of CVD events (coronary heart disease and stroke), labour costs (pharmacist and physician visits) and medications.
Reference
Yu J, et al. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California. Journal of Managed Care Pharmacy 19: 102-14, No. 2, Mar 2013
Rights and permissions
About this article
Cite this article
Pharmacist care cost effective for CVD prevention in diabetes. PharmacoEcon Outcomes News 674, 7 (2013). https://doi.org/10.1007/s40274-013-0246-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0246-4